BOTHELL, Wash., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 supporting development for the prevention of migraine, and preclinical data from a case study of ALD403 and other CGRP-antibodies will be presented at the upcoming 5th European Headache and Migraine Trust International Congress (EHMTIC 2016) on September 15-18, 2016 in Glasgow, U.K.

• Poster presentation: “Randomized, Double-Blind, Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody in the Prevention of Chronic Migraine”
  
  Poster #: EHMTC-0410
  Session Title: Poster Discussion Session A
  Session Date: Friday, September 16, 2016
  Session Time: 1:00 am – 12:30 pm BST
  
  

• Poster presentation: “A Multiple-Dose, Phase I Placebo-Controlled, Randomized Study of ALD403, An Anti-CGRP Antibody, Administered Every 3-Months via IV, SC, or IM”
  
  Poster #: EHMTC-0397
  Session Title: Poster Discussion Session A
  Session Date: Friday, September 16, 2016
  Session Time: 11:00 am – 12:30 pm BST
  
  

• Poster presentation: “Characterization of the Binding of Three Anti-CGRP Antibodies Effective in Preventing Migraine: A Comparative Case Study of ALD403, LY-2951742, TEV-48125”
  
  Poster #: EHMTC-0359
  Session Title: Poster Discussion Session E
  Session Date: Saturday, September 17, 2016
  Session Time: 6:30 pm – 7:30 pm BST
  
  

About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, ALD403, is being evaluated for migraine prevention. ALD403 is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.

Media Contacts:			
David Schull or Todd Davenport, Ph.D.	
Russo Partners, LLC			
(212) 845-4271				
(212) 845-4235				
david.schull@russopartnersllc.com 
todd.davenport@russopartnersllc.com 

Investor Relations Contact:
David Walsey
Alder BioPharmaceuticals
(425) 408-8032
ir@alderbio.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.